Key Developments: Ab Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

16.84EUR
27 Feb 2015
Change (% chg)

€-0.13 (-0.77%)
Prev Close
€16.97
Open
€16.96
Day's High
€16.99
Day's Low
€16.61
Volume
78,944
Avg. Vol
195,081
52-wk High
€18.93
52-wk Low
€7.16

Search Stocks

Latest Key Developments (Source: Significant Developments)

AB Science SA announced the successful completion of futility test for masitinib in Alzheimer
Monday, 9 Feb 2015 03:34pm EST 

AB Science SA:Announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer's disease.Independent Data Safety Monitoring Committee (IDMC) has recommended the continuation of study.  Full Article

AB Science SA announces positive phase 2 clinical study data of masitinib in second-line metastatic stomach cancer
Monday, 2 Feb 2015 12:26pm EST 

AB Science SA:Announces encouraging efficacy and safety results from phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic esophagogastric adenocarcinoma after progression to first-line treatment.This was prospective, multicenter, open-label, randomized, uncontrolled, phase 1b/2 study to evaluate efficacy and safety of masitinib in association with chemotherapy for treatment of recurrent gastric or gastro-esophageal junction adenocarcinoma.Patients received masitinib in combination with irinotecan, or FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), or 5-fluorouracil, after progression to platinum-based first-line chemotherapy.  Full Article

AB Science says DSMB recommends continuation of phase 3 study of masitinib in amyotrophic lateral sclerosis
Tuesday, 13 Jan 2015 11:44am EST 

AB Science SA:Data And Safety Monitoring Board (DSMB) recommends the continuation of phase 3 study of masitinib in amyotrophic lateral sclerosis.On-Going phase 3 clinical trial is an international, multicenter, randomized, double-blind study comparing efficacy and safety of masitinib with that of placebo.  Full Article

AB Science reports positive follow-up results with masitinib
Thursday, 18 Dec 2014 12:02pm EST 

AB Science SA:Reports positive clinical study data in metastatic colorectal cancer.Encouraging follow-up results from phase 2 study with masitinib, in patients with nonresectable, metastatic colorectal cancer after progression to first-line treatment.  Full Article

AB Science advances SYK kinase inhibitor into full preclinical development
Friday, 28 Nov 2014 11:53am EST 

AB Science SA:Ultra-Selective SYK Kinase Inhibitor advanced into full preclinical development.Novel small molecule SYK Kinase Inhibitor is named AB8779.Inhibition of SYK is considered to be therapeutic strategy for B-cell malignancies, including non-Hodgkin lymphoma (NHL).Inhibition of SYK is considered to be therapeutic strategy for chronic lymphocytic leukemia (cll), asthma and rheumatoid arthritis.  Full Article

AB Science says Data and Safety Monitoring Board recommends continuation of Phase 2 study with masitinib
Wednesday, 12 Nov 2014 11:47am EST 

AB Science SA:Says Data and Safety Monitoring Board recommends continuation of Phase 2 study with masitinib in advanced hepatocellular carcinoma.  Full Article

AB Science announces positive preclinical results of studies on masitinib
Thursday, 30 Oct 2014 01:06pm EDT 

AB Science SA:Announces positive preclinical results of studies on masitinib.Findings showed that masitinib reduced stroke-related brain infarct size in animal model of stroke.Masitinib may be recommended as appropriate candidate for further development of novel neuroprotective strategies, including in acute ischemic stroke.  Full Article

AB Science DSMB recommends the continuation of phase 3 study of masitinib in progressive forms of multiple sclerosis
Monday, 6 Oct 2014 12:00pm EDT 

AB Science SA:Says the Data and Safety Monitoring Board (DSMB) recommends the continuation of the phase 3 study of masitinib in progressive forms of multiple sclerosis.Says results confirm there are no observed safety concerns with masitinib over a two-year treatment period.  Full Article

AB Science says DSMB recommends continuation of its phase 3 study of Masitinib in mastocytosis
Tuesday, 30 Sep 2014 11:49am EDT 

AB Science SA:Says external Data and Safety Monitoring Board (DSMB) has recommended continuation of its phase 3 study of Masitinib in mastocytosis.Says final analysis of trial data is still planned for 2015.  Full Article

AB Science announces publication of results from randomized phase 2 study of masitinib
Monday, 28 Jul 2014 02:01am EDT 

AB Science SA:Announces publication of results from randomized phase 2 study of masitinib in treatment of Gleevec-resistant gastrointestinal stromal tumor.Findings showed masitinib to produce statistically significant overall survival (OS) advantage of 12.4 months in patients with Gleevec-resistant GIST.Primary efficacy analysis ensured masitinib treatment arm could satisfy prespecified progression-free survival (PFS) threshold.Secondary efficacy analysis showed that masitinib followed by standard of care generated survival benefit over standard of care.International phase 3 trial of masitinib in patients with Gleevec-resistant/intolerant GIST has been initiated based on these promising results.  Full Article

BRIEF-Ab Science Q4 revenue rises to 544,000 euros

* Q4 revenue of 544,000 euros ($608,736) versus 496,000 euros year ago

Search Stocks